In addition, several studies in HER2+ breast cancer cell lines have correlated calpain expression with resistance to chemotherapeutics such as trastuzumab, doxorubicin and cisplatin (Kulkarni et al., 2010; Grieve et al., 2016; Al-Bahlani et al., 2017; MacLeod et al., 2018). Here, ERBB2 is linked to breast cancer.